dipyridamole has been researched along with Coronavirus Infections in 4 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Coronavirus Infections: Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Indeed, Kawasaki disease is induced by overreaction of innate cells following exposition to various viruses, including herpes viruses which trigger STING." | 2.66 | Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway? ( Berthelot, JM; Drouet, L; Lioté, F, 2020) |
| "Counterproductive lung inflammation and dysregulated thrombosis contribute importantly to the lethality of advanced COVID-19." | 1.56 | Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole. ( Barroso-Aranda, J; DiNicolantonio, JJ, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanthi, Y | 1 |
| Knight, JS | 1 |
| Zuo, Y | 1 |
| Pinsky, DJ | 1 |
| Berthelot, JM | 1 |
| Drouet, L | 1 |
| Lioté, F | 1 |
| DiNicolantonio, JJ | 1 |
| Barroso-Aranda, J | 1 |
| Li, Z | 1 |
| Li, X | 1 |
| Huang, YY | 1 |
| Wu, Y | 1 |
| Liu, R | 1 |
| Zhou, L | 1 |
| Lin, Y | 1 |
| Wu, D | 1 |
| Zhang, L | 1 |
| Liu, H | 1 |
| Xu, X | 1 |
| Yu, K | 1 |
| Zhang, Y | 1 |
| Cui, J | 1 |
| Zhan, CG | 1 |
| Wang, X | 1 |
| Luo, HB | 1 |
1 review available for dipyridamole and Coronavirus Infections
| Article | Year |
|---|---|
Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway?
Topics: Angiotensin II; Animals; Aspirin; Blood Coagulation Disorders; Coronavirus Infections; COVID-19; Dip | 2020 |
3 other studies available for dipyridamole and Coronavirus Infections
| Article | Year |
|---|---|
New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Betacoronavirus; Coronavirus Infections; COVID-19; CO | 2020 |
Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole.
Topics: Adenosine A2 Receptor Agonists; Animals; Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; C | 2020 |
Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; CO | 2020 |